Despite the knowledge that ineligibility factors, such as low albumin or prealbumin and elevated bilirubin levels, are associated with mortality and morbidity, the prevalence of trial ineligibility among recipients of LVADs has not changed over time.13 The FDA and clinical trialists may use findings from this study to refine future trial eligibility criteria to be more representative of real-world LVAD recipients and may consider eliminating criteria that may have no association with mortality (eg, thrombocytopenia). The gene discussed is ALB; the disease is Thrombocytopenia.